[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201891882A1 - НОВЫЕ АНТИТЕЛА К SIRPa И ВАРИАНТЫ ИХ ТЕРАПЕВТИЧЕСКОГО ПРИМЕНЕНИЯ - Google Patents

НОВЫЕ АНТИТЕЛА К SIRPa И ВАРИАНТЫ ИХ ТЕРАПЕВТИЧЕСКОГО ПРИМЕНЕНИЯ

Info

Publication number
EA201891882A1
EA201891882A1 EA201891882A EA201891882A EA201891882A1 EA 201891882 A1 EA201891882 A1 EA 201891882A1 EA 201891882 A EA201891882 A EA 201891882A EA 201891882 A EA201891882 A EA 201891882A EA 201891882 A1 EA201891882 A1 EA 201891882A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sirpa
options
new antibodies
therapeutic application
interaction
Prior art date
Application number
EA201891882A
Other languages
English (en)
Inventor
Николя Пуарье
Каролина Мари
Бернард Ванхове
Ванесса Готье
Виржини Тепенье
Сабрина Пенгам
Original Assignee
Осе Иммьюнотерапьютикс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Осе Иммьюнотерапьютикс filed Critical Осе Иммьюнотерапьютикс
Publication of EA201891882A1 publication Critical patent/EA201891882A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение относится к новым антителам к SIRPa, способным оказывать специфическое антагонистическое действие на взаимодействие SIRPa с CD47, не оказывая отрицательного влияния на взаимодействие SIRPg с CD47, а также к вариантам их применения.
EA201891882A 2017-02-17 2017-04-14 НОВЫЕ АНТИТЕЛА К SIRPa И ВАРИАНТЫ ИХ ТЕРАПЕВТИЧЕСКОГО ПРИМЕНЕНИЯ EA201891882A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305182 2017-02-17
PCT/EP2017/059071 WO2017178653A2 (en) 2016-04-14 2017-04-14 NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS

Publications (1)

Publication Number Publication Date
EA201891882A1 true EA201891882A1 (ru) 2019-07-31

Family

ID=58185461

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891882A EA201891882A1 (ru) 2017-02-17 2017-04-14 НОВЫЕ АНТИТЕЛА К SIRPa И ВАРИАНТЫ ИХ ТЕРАПЕВТИЧЕСКОГО ПРИМЕНЕНИЯ

Country Status (11)

Country Link
EP (1) EP3443010B1 (ru)
CN (1) CN109071664B (ru)
AU (1) AU2017248626B2 (ru)
BR (1) BR112018070823A2 (ru)
CA (1) CA3020373A1 (ru)
CO (1) CO2018010855A2 (ru)
EA (1) EA201891882A1 (ru)
PE (1) PE20181921A1 (ru)
PT (1) PT3443010T (ru)
SG (1) SG11201808465UA (ru)
WO (1) WO2017178653A2 (ru)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018001428A (es) 2015-08-07 2018-09-05 Alx Oncology Inc Construcciones con un dominio sirp-alfa o sus variantes.
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
KR20240039236A (ko) 2016-12-09 2024-03-26 알렉터 엘엘씨 항-sirp-알파 항체 및 그의 사용 방법
CN110300764A (zh) * 2017-02-17 2019-10-01 Ose免疫疗法 抗SIRPg抗体的新用途
MX2019012233A (es) 2017-04-13 2020-01-14 Aduro Biotech Holdings Europe Bv Anticuerpos anti-sirpa.
KR102714600B1 (ko) * 2017-05-16 2024-10-08 비온디스 비.브이. 항-SIRPα 항체
AU2018312222A1 (en) 2017-08-02 2020-02-27 Phanes Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
JP7395471B2 (ja) * 2017-10-13 2023-12-11 オーセ イミュノセラピューティクス 改変抗ＳＩＲＰａ抗体及びその使用
EP3700938A1 (en) * 2017-10-26 2020-09-02 ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. Novel recombinant fusion proteins, preparation and use thereof
CA3091468A1 (en) * 2018-03-13 2019-09-19 Ose Immunotherapeutics Use of anti-human sirpa v1 antibodies and method for producing anti-sirpa v1 antibodies
US20210047436A1 (en) * 2018-03-14 2021-02-18 Memorial Sloan Kettering Cancer Center Anti- polysialic acid antibodies and uses thereof
CA3094098A1 (en) * 2018-03-21 2019-09-26 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
WO2019226973A1 (en) 2018-05-25 2019-11-28 Alector Llc Anti-sirpa antibodies and methods of use thereof
JP7368809B2 (ja) 2018-07-10 2023-10-25 国立大学法人神戸大学 抗ＳＩＲＰα抗体
US20230242640A1 (en) * 2018-08-22 2023-08-03 Ose Immunotherapeutics ANTI-SIRPg Compounds
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
SG11202102851XA (en) 2018-09-27 2021-04-29 Celgene Corp SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF
JP2022509480A (ja) 2018-10-29 2022-01-20 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー 好中球のＣＤ４７－ＳＩＲＰアルファチェックポイント阻害による異常な細胞のＩｇＡによって媒介される致死
BR112021009325A2 (pt) * 2018-11-14 2021-09-14 Arch Oncology, Inc. Anticorpo monoclonal, ou fragmento de ligação ao antígeno do mesmo; anticorpo biespecífico; método para prevenir ou tratar um câncer suscetível em um ser humano; método de ensaio de expressão de sirp¿ em células tumorais e/ou imunes; e; composição farmacêutica
US20210388107A1 (en) 2018-11-15 2021-12-16 Byondis B.V. Humanized anti-sirp alpha antibodies
JP2022514698A (ja) * 2018-12-21 2022-02-14 オーエスイー・イミュノセラピューティクス 二機能性抗ｐｄ－１／ｓｉｒｐａ分子
WO2020176790A1 (en) * 2019-02-27 2020-09-03 Fred Hutchinson Cancer Research Center Hydrogel compositions and methods for treatment of malignancies
WO2020180811A1 (en) * 2019-03-04 2020-09-10 Qilu Puget Sound Biotherapeutics Corporation Anti-sirp-alpha antibodies
EP3976099A1 (en) 2019-05-31 2022-04-06 ALX Oncology Inc. Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
CN114206912A (zh) 2019-06-07 2022-03-18 Alx肿瘤生物技术公司 用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂
EP3756688A1 (en) 2019-06-25 2020-12-30 Université de Nantes Inhibitor of surface protein (sp-d) / sirpa / shp2 pathway for use in the prevention and/or treatment of secondary infection
CA3142513A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
JP2022545300A (ja) * 2019-08-20 2022-10-27 エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド 新規の抗ｓｉｒｐａ抗体
CA3208912A1 (en) 2019-10-18 2021-04-22 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
EP4052040A1 (en) 2019-10-31 2022-09-07 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
JP2023503943A (ja) 2019-11-27 2023-02-01 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための組み合わせ療法
CN117736207A (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
CN111116713B (zh) * 2020-01-07 2023-06-23 郑州大学 Sirpa蛋白亲和环肽及其应用
AU2021219668A1 (en) 2020-02-14 2022-08-25 Gilead Sciences, Inc. Antibodies and fusion proteins that bind to CCR8 and uses thereof
US11920136B2 (en) 2020-02-28 2024-03-05 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
TW202214303A (zh) 2020-05-19 2022-04-16 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之結合分子
KR20230018475A (ko) 2020-06-01 2023-02-07 알렉소 온콜로지 인크. 암 치료용 저메틸화제를 포함하는 병용 요법
US20230414778A1 (en) 2020-11-11 2023-12-28 Daiichi Sankyo Company, Limited COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY
JP2024501134A (ja) 2020-11-30 2024-01-11 クレ バイオテクノロジ （シャンハイ） カンパニー リミテッド 抗ＳＩＲＰα抗体またはその抗原結合断片および適用
WO2022120286A1 (en) 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
EP4337190A1 (en) 2021-05-13 2024-03-20 ALX Oncology Inc. Combination therapies for treating cancer
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
CN117355539A (zh) * 2021-05-28 2024-01-05 百奥泰生物制药股份有限公司 抗SIRPα抗体及其应用
KR20240027677A (ko) 2021-06-04 2024-03-04 베링거 인겔하임 인터내셔날 게엠베하 항-sirp-알파 항체
AU2022297367A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022298639B2 (en) 2021-06-23 2024-11-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
MX2023013915A (es) 2021-06-29 2024-01-25 Seagen Inc Métodos para tratar el cáncer con una combinación de un anticuerpo anti-cd70 no fucosilado y un antagonista de cd47.
EP4389767A1 (en) 2021-08-17 2024-06-26 Hangzhou Jiuyuan Gene Engineering Co., Ltd Monoclonal antibody targeting sirp? and use thereof
AU2022375782A1 (en) 2021-10-28 2024-05-02 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CR20240173A (es) 2021-10-29 2024-06-20 Gilead Sciences Inc Compuestos de cd73
CN118679183A (zh) 2021-11-29 2024-09-20 Ose免疫疗法公司 特异性拮抗剂抗sirpg抗体
KR20240125012A (ko) 2021-12-22 2024-08-19 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
AU2022419982A1 (en) 2021-12-22 2024-06-06 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
AU2023233730A1 (en) 2022-03-17 2024-09-26 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
AU2023256670A1 (en) 2022-04-21 2024-10-17 Gilead Sciences, Inc. Kras g12d modulating compounds
TW202408584A (zh) 2022-05-10 2024-03-01 日商第一三共股份有限公司 抗體-藥物結合物與抗SIRPα抗體之組合
WO2023235754A1 (en) 2022-06-01 2023-12-07 ALX Oncology Inc. Combination therapies for treating urothelial carcinoma
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024105180A1 (en) 2022-11-16 2024-05-23 Boehringer Ingelheim International Gmbh Predictive efficacy biomarkers for anti-sirpa antibodies
WO2024137852A1 (en) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024200826A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100215640A1 (en) * 2003-04-24 2010-08-26 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
US8613922B2 (en) * 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US20090191202A1 (en) * 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
CN101970478A (zh) * 2007-10-11 2011-02-09 大学健康网络 调节SIRPα-CD47相互作用以增加造血干细胞植入以及用于此的化合物
CN101780283A (zh) * 2010-03-16 2010-07-21 中国人民解放军第二军医大学 信号调节蛋白α在制备预防和治疗肿瘤的DC疫苗中的应用
CN101880324B (zh) * 2010-05-25 2012-10-17 中国人民解放军第二军医大学 一种抗人SIRPα的单克隆抗体及其细胞株、制备方法和应用
SG11201607143UA (en) * 2014-03-11 2016-09-29 Univ Leland Stanford Junior Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies

Also Published As

Publication number Publication date
CN109071664A (zh) 2018-12-21
CN109071664B (zh) 2023-02-21
AU2017248626B2 (en) 2024-05-09
WO2017178653A2 (en) 2017-10-19
EP3443010B1 (en) 2024-08-07
BR112018070823A2 (pt) 2019-02-05
EP3443010A2 (en) 2019-02-20
AU2017248626A1 (en) 2018-10-11
WO2017178653A3 (en) 2018-07-05
CO2018010855A2 (es) 2018-11-13
PE20181921A1 (es) 2018-12-11
CA3020373A1 (en) 2017-10-19
SG11201808465UA (en) 2018-10-30
PT3443010T (pt) 2024-10-21

Similar Documents

Publication Publication Date Title
EA201891882A1 (ru) НОВЫЕ АНТИТЕЛА К SIRPa И ВАРИАНТЫ ИХ ТЕРАПЕВТИЧЕСКОГО ПРИМЕНЕНИЯ
CL2019002824A1 (es) Anticuerpos anti-lag3.
CL2019000424A1 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
CY1123259T1 (el) Αντισωματα anti-pvrig και μεθοδοι χρησης
EA201890441A1 (ru) Моноклональные антитела против bcma
CO2019003943A2 (es) Proteínas de fusión fc heterodiméricas il15/il15rα
EA201691991A1 (ru) Мультиспецифические антитела
SA517381604B1 (ar) أجسام مضادة ديمرية غير متجانسة جديدة
BR112017008666A2 (pt) anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201890093A1 (ru) Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина
EA201790548A1 (ru) Варианты комбинированной терапии анти-cd38 антителами
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201690314A1 (ru) Анти-garp-белок и его применения
CL2020002540A1 (es) Anticuerpos anti-hla-g y utilización de los mismos
PH12018550160A1 (en) NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
EA201892716A1 (ru) Антитела к фактору свертывания xi
EA201891299A1 (ru) Терапевтические антитела к cd9
EA202091521A1 (ru) ВАРИАНТЫ ДОМЕНА Fc IgG ЧЕЛОВЕКА С УЛУЧШЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
EA201890347A1 (ru) Антитела и исследования для обнаружения cd37